Article
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology - 1 Dec 2020
Thomas Cameron D, Mosley Scott A, Kim Sarah, Lingineni Karthik, El Rouby Nihal, Langaee Taimour Y, Gong Yan, Wang Danxin, Schmidt Siegfried O, Binkley Philip F, Estores David S, Feng Kairui, Kim Hyewon, Kinjo Minori, Li Zhichuan, Fang Lanyan, Chapman Arlene B, Cooper-DeHoff Rhonda M, Gums John G, Hamadeh Issam S, Zhao Liang, Schmidt Stephan, Frye Reginald F, Johnson Julie A, Cavallari Larisa H
Abstract excerpt
Recent CYP2D6 phenotype standardization efforts by CYP2D6 activity score (AS) are based on limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Using data from two independent clinical trials of metoprolol, we compared metoprolol PK and PD across CYP2D6 AS with the goal of determining whether the PK and PD data support the new phenotype classification. S-metoprolol apparent oral clearance (CLo), adjusted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.